Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.
about
No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled studyRoflumilast (daliresp): a novel phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary diseaseTreatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary diseasePharmacokinetic evaluation of roflumilast.Roflumilast: a novel treatment for chronic obstructive pulmonary disease.Pharmacokinetic behavior presents drug therapy challenges.Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations.Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis.Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults.Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects.Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors
P2860
Q33919207-BD4FCA03-99A9-4712-943D-FD78906ACDDEQ35958704-70A169AD-7F63-40FE-8430-1399B6AE72B2Q37732234-C4CD74AF-B386-4B33-9CB3-256D0BA8DBD2Q37778289-4D93AB00-F43A-47EB-BDFA-C7071A82DF35Q37828179-BF4F7859-3627-4086-B95C-58831044B8DAQ37953446-17F0027E-AA77-4A18-BA34-C3ED46DEBE35Q37995404-B9E1D867-25C2-4EEB-8899-DF801816A0CFQ38155930-053E6F23-A78F-4BD1-ABB7-C1CFA7B7580CQ39020015-58E635A8-EAD1-4FB8-91EC-EA4BB16C21EDQ39899497-FAB6624E-1C56-42BE-8171-01F557B4B828Q43237082-9CE6EAC5-0307-4ACE-8E0E-C8974E0D2B1BQ51513880-FAAD5A3D-2B24-40BF-BC36-0D9975AAB995Q51568037-FE5505D7-52AE-48A8-A817-F0318785286DQ57009464-BBA816E9-D890-4E4F-BAE4-68114B05B729
P2860
Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Effects of rifampicin on the p ...... t N-oxide in healthy subjects.
@en
Effects of rifampicin on the p ...... t N-oxide in healthy subjects.
@nl
type
label
Effects of rifampicin on the p ...... t N-oxide in healthy subjects.
@en
Effects of rifampicin on the p ...... t N-oxide in healthy subjects.
@nl
prefLabel
Effects of rifampicin on the p ...... t N-oxide in healthy subjects.
@en
Effects of rifampicin on the p ...... t N-oxide in healthy subjects.
@nl
P2093
P2860
P1476
Effects of rifampicin on the p ...... t N-oxide in healthy subjects.
@en
P2093
Andreas Huennemeyer
Gezim Lahu
Kevin Duffy
Manuela Koch
Nassr Nassr
Oliver von Richter
Robert Hermann
Rolf Herzog
P2860
P304
P356
10.1111/J.1365-2125.2009.03478.X
P407
P577
2009-10-01T00:00:00Z